As the news cycle goes, headlines are rolling into the January US Federal Open Market Committee meeting that begins today.

According to Sanofi, tolebrutinib is the first investigational BTK inhibitor with the ability ... s daily walking patterns using the Google Maps Timeline tool may help doctors remotely monitor ...

Video content above is prompted by the following: The ASH abstract by Mansour and colleagues suggests that for patients who have been on BTK inhibitors for more than 2 years, discontinuing therapy ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations ...

Some Chiefs players received a sendoff at the Boys & Girls Club Disgraced former US Senator Bob Menendez weeps as he's ...

Learn more. Please also consider subscribing to WIRED It's totally understandable if you haven’t opened Apple Maps since its disastrous launch in 2012, which among other things saw people ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Sands, M.D., Ph.D., president and chief executive officer of Nurix. “John’s experience commercializing the BTK inhibitor ibrutinib as well as his experience building commercial teams ahead of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Northcott brings over two decades of commercial experience to Nurix, having previously led commercialization efforts for the first marketed BTK inhibitor, ibrutinib. The company, currently valued ...

MCL, affecting an estimated 21,000 people globally, has limited treatment options. Calquence, the first BTK inhibitor approved for initial MCL treatment in the US, is a crucial advancement ...

The US regulator has placed oral BTK inhibitor orelabrutinib on partial clinical hold, meaning new patients cannot be enrolled into clinical trials and patients treated with the drug for 70 days ...